Short Bowel Syndrome Market Set for Explosive Growth to US$ 7.93 Billion by 2033, Led by North America's 45% Market Share | Key Players - Takeda Pharmaceutical Company Limited, VectivBio AG, Nutrinia

The Global Short Bowel Syndrome Market was valued at US$ 1.64 billion in 2024 and is expected to reach US$ 7.93 billion by 2033, growing at a CAGR of 19.3% during the forecast period 2025-2033.

Market expansion is propelled by the rising prevalence of short bowel syndrome linked to intestinal surgeries, Crohn's disease, and congenital anomalies, alongside increased survival rates from pediatric surgeries. Advancements in GLP-2 analogs like teduglutide, growing adoption of parenteral nutrition, and innovative therapies improving nutrient absorption are accelerating demand.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/short-bowel-syndrome-market?ram

Key Industry Developments

United States:
✅ February 2026: Ironwood Pharmaceuticals advanced apraglutide into late-stage trials with positive topline data from Phase 3 studies, demonstrating significant reduction in parenteral support volume for SBS patients, positioning it as a next-gen GLP-2 agonist for FDA approval in 2027. This builds on prior orphan drug status and aims to improve long-term independence from TPN, addressing key unmet needs in adult SBS-IF management.

✅ January 2026: Napo Pharmaceuticals released expanded proof-of-concept results for crofelemer liquid formulation, showing up to 15% further reduction in TPN dependency in Phase 2 cohorts, leveraging its anti-secretory mechanism for better fluid balance. The data supports ongoing R&D for a novel adjunctive therapy, with plans for pivotal trials targeting US market entry.

✅ November 2025: Zealand Pharma confirmed FDA Type A meeting outcomes for glepaglutide, finalizing EASE-5 Phase 3 design as a long-acting GLP-2 for weekly dosing to minimize parenteral nutrition in SBS. Trial start in H2 2025 paves way for US resubmission, enhancing treatment adherence over daily options like Gattex.

Asia Pacific / Japan:
✅ December 2025: Hanmi Pharm initiated multi-center Phase 2 recruitment for sonefpeglutide in Japan via MFDS collaboration, highlighting its once-monthly LAPSCOVERY platform for SBS-IF with fast-track orphan designation. Interim data expected 2026 could disrupt regional parenteral support reliance, aligning with Japan's aging population needs.

✅ October 2025: Takeda expanded Revestive (teduglutide) pediatric access in Japan post-MHLW approval update, incorporating real-world evidence from Asia trials for younger SBS cohorts requiring growth support. This R&D milestone boosts market penetration amid rising post-surgical cases in APAC.

✅ September 2025: Zealand Pharma's glepaglutide MAA submission to EMA influenced Japan PMDA consultations, advancing liquid autoinjector tech for SBS with reduced injection frequency and improved patient QoL. Regional trials underscore technological edge in GLP-2 delivery for Asia-Pacific markets.

Key Players:
Takeda Pharmaceutical Company Limited | OxThera Inc | VectivBio AG | Nutrinia | Merck KGaA | Pfizer Inc. | Ardelyx | Zealand Pharma | Nestlé S.A.

Strategic Leadership Report: Top 5 Players in Short Bowel Syndrome Market 2026
-Takeda Pharmaceutical Company Limited: Advanced GATTEX (teduglutide) with FDA approval for pediatric patients aged 1 year and older with SBS, enabling reduced parenteral support volume by up to 42% and potential independence from IV nutrition in clinical studies.

-Zealand Pharma: Launched survodutide, a dual GLP-1/glucagon receptor agonist showing promise in enhancing intestinal adaptation and reducing SBS dependency on parenteral nutrition through Phase 2 trials focused on gut hormone modulation.

-Pfizer Inc.: Introduced novel GLP-2 analogs under development for SBS, featuring extended half-life formulations that improve nutrient absorption and bowel function, as highlighted in recent pipeline updates for rare GI disorders.

-Merck KGaA: Developed teduglutide biosimilars with optimized delivery systems for SBS management, providing cost-effective alternatives that support long-term reduction in parenteral support needs via enhanced mucosal growth.

-Nestlé S.A.: Rolled out Peptamen AF enteral nutrition formula tailored for SBS patients, incorporating bioactive peptides for better tolerance and absorption to minimize complications from short bowel malabsorption.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=short-bowel-syndrome-market?ram

Market Drivers and Key Trends:
-Rising Disease Prevalence: Increasing incidence of short bowel syndrome from surgical resections, inflammatory bowel disease, and premature births drives demand for advanced therapies.

-Therapeutic Innovations: GLP-2 analogues like teduglutide and advancements in regenerative medicine promote intestinal adaptation, reducing parenteral nutrition dependency.

-Microbiome Modulation: Gut microbiota manipulation enhances nutrient absorption and intestinal health, boosting treatment efficacy.

-Awareness and Diagnostics: Improved early detection, growing awareness of rare diseases, and rising geriatric population expand the addressable patient pool.

-R&D Collaborations: Partnerships between pharma companies like Takeda, Merck, and biotech firms accelerate novel drug development and biologics.

-Market Hurdles: High treatment costs, long-term safety concerns like neoplasia risks, supply chain issues for peptides, and stringent regulations limit scalability.

Regional Insights:
-North America holds the largest share of the Short Bowel Syndrome market at 45%, driven by advanced healthcare infrastructure, early adoption of biologic therapies like GLP-2 analogs, and strong reimbursement policies.

-Asia Pacific follows with 25% share (fastest growing at 9.5% CAGR), fueled by expanding R&D investments, rising clinical trials, and increasing awareness in countries like China and India.

-Europe accounts for 20% (steady growth via regulatory support and pipeline developments), while Latin America and Middle East & Africa together hold the remaining 10%, supported by emerging demand for advanced treatments.

Market Opportunities & Challenges: Short Bowel Syndrome Market 2026
-Opportunities:
GLP-2 analog expansions enable home-based parenteral nutrition weaning, accelerating outpatient transitions for long-term remitters. Orphan drug incentives and next-gen somatostatin modulators streamline regulatory paths for rare pediatric indications.

-Challenges:
High-cost biologics strain reimbursement frameworks amid payer scrutiny, while parenteral nutrition infections elevate hospitalization risks. Manufacturing scale-up delays for oral rexinoids hinder supply chain resilience in decentralized care models.

-Strategic Verdict:
Precision nutraceutical platforms and AI-driven absorption forecasting emerge as dominant vectors for 2026 scalability.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/short-bowel-syndrome-market?ram

Market Segmentation Analysis:
-By Drug Class: GLP-2 Dominates with Proven Efficacy
GLP-2 analogs lead at 60% market share in 2024, excelling in promoting intestinal adaptation and nutrient absorption for short bowel syndrome (SBS) patients via teduglutide-like therapies.
Growth hormone follows at 25%, supporting mucosal growth but limited by injection frequency and side effects.
Glutamine holds 10%, aiding gut barrier function as an affordable oral supplement.
Others capture 5%, including emerging biologics with niche roles in symptom management.

-By Distribution Channel: Hospital Pharmacies Lead in Specialized Care
Hospital pharmacies command 55% share, vital for IV infusions and monitoring in severe SBS cases requiring inpatient oversight.
Retail pharmacies take 30%, offering convenient refills for stable outpatients.
Others, like specialty and online channels, account for 15%, growing via home delivery for chronic therapy adherence.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.